

<http://dx.doi.org/10.3126/njdvl.v17i1.23333>

# Upcoming Therapeutic Modalities for the Treatment of Keloids: An Update

Keyal U<sup>1,2</sup>, Bhatta AK<sup>2</sup>

<sup>1</sup>Sumeru City Hospital, Pulchowk, Nepal; <sup>2</sup>Let Me In Korean Aesthetic Skin Hospital, Baneshwor, Kathmandu, Nepal

## Abstract

**Introduction:** Keloids are benign dermal tumors that generally form by local fibroblast proliferation and excessive collagen production following skin trauma. Several methods have been described for the treatment of keloid, often with suboptimal results and recurrences.

**Objective:** To update literature that provides information regarding upcoming therapeutic modalities for the treatment of keloids, including lasers, radiofrequency (RF), photodynamic therapy (PDT), and ultraviolet A1 (UVA1) irradiation.

**Materials and Methods:** A systematic review of the literature was performed for the original articles related to the treatment of keloids. The search terms 'keloids' and 'lasers' or 'radiofrequency' or 'PDT' or 'UVA1' was entered into a search of the National Library of Medicine's PubMed Database.

**Result:** The search returned a total of 188 sources, of which, 26 articles met our inclusion criteria.

**Conclusion:** Combination approach is superior than solo therapy in the treatment of keloid. However, it is highly desirable that new emerging therapies undergo large-scale studies with long-term follow-up before being recommended conclusively as alternative therapies for the treatment of keloid. Moreover, lack of randomized clinical trials (RCTs) needs to be taken into consideration urgently.

**Key words:** Collagen; Fibroblasts; Keloid; Photochemotherapy; Ultraviolet Therapy

## Introduction

Keloids are benign dermal tumors that generally form by local fibroblast proliferation and excessive collagen production following skin trauma.<sup>1</sup> Rarely, it can occur spontaneously in the absence of antecedent trauma.<sup>2</sup> Keloids are unique to human and occur more frequently in individuals with darker skin.<sup>3</sup> The propensity of keloid formation in darker skin types is thought to be due in part by the larger multinucleated fibroblasts that have been described in this population.<sup>4</sup> Keloids vary in size and shape, and do not regress spontaneously. They can be pedunculated or elevated with a flat surface, and may grow to sizes that can be disfiguring or crippling. Keloids range in consistency from soft and doughy to rubbery hard and they may be tender, painful, pruritic, or cause a burning sensation.<sup>5</sup> Histologically, they are characterized by exuberant dermal collagen formation with random

orientation and assembly of the individual collagen fibers. Uncontrolled fibroblast activity and excess collagen lead to overabundant extracellular matrix formation, and are the hallmark of these tumors.<sup>6</sup> Although the exact pathogenesis of keloid is not elucidated, it has been known that keloid fibroblasts, when compared with normal fibroblasts, have lower rates of apoptosis.<sup>7</sup> In addition, these cells overproduce type I collagen and express higher levels of cytokines and growth factors, which influences

Submitted: 2<sup>nd</sup> November 2018

Accepted: 1<sup>st</sup> February 2019

Published: 31<sup>st</sup> March 2019

### How to cite this article

Keyal U, Bhatta AK. Upcoming therapeutic modalities for the treatment of keloids: an update. *Nepal Journal of Dermatology Venereology and Leprology*. 2019;17(1):2-11. doi: <http://dx.doi.org/10.3126/njdvl.v17i1.23333>



Licensed under CC BY 4.0 International License which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

### Address of Correspondence:

Dr. Anil Kumar Bhatta, PhD

Consultant Dermatologist

Let Me In Korean Aesthetic Skin Hospital,

Baneshwor, Kathmandu, Nepal

E-mail: [bhattaanil@yahoo.com](mailto:bhattaanil@yahoo.com)

proliferation and collagen synthesis by fibroblasts. Another factor studied in the pathogenesis of keloid formation is the role of increased skin tension. This has postulated the skin injury–wound tension theory as the corner stone theory for keloid formation.<sup>1</sup> A wide range of treatment modalities for keloid exists, which includes cryotherapy, surgical excision, intralesional injection with pharmacologic agents, mechanical pressure, and silicone gel dressings. None of these are 100% successful. Moreover, studies have shown lowered self-esteem and impaired quality of life in affected individuals.<sup>8</sup> This calls for the investigation of new therapeutic interventions. Recently, attention has been drawn to the possible beneficial effects of newer therapies like lasers, radiofrequency, photodynamic therapy, and UVA1 irradiation. In the present review, we aim to update literature that provides information regarding upcoming therapeutic modalities for the treatment of keloids.

Many different lasers have been studied and utilized in the treatment of keloids including carbon dioxide (CO<sub>2</sub>) laser, 2940-nm erbium-doped: yttrium, aluminum and garnet (Er:YAG) laser, 1064-nm neodymiumdoped:yttrium, aluminum and garnet (Nd:YAG) laser, and 585-595 nm pulsed-dye lasers (PDL). CO<sub>2</sub> and Er:YAG are ablative lasers, while Nd:YAG and PDL are non ablative lasers. CO<sub>2</sub> laser and Er:YAG laser emit beams absorbed by water in skin resulting in local tissue destruction.<sup>9,10</sup> Since the energy of the Er:YAG laser is due to its wavelength (2,940 nm) – largely absorbed by water, there is only very minor heat dissipation into the surrounding tissue; hence the term “cold” tissue ablation.<sup>11</sup> The CO<sub>2</sub> laser, on the other hand, with a wavelength of 10,600 nm, generates more heat in the surrounding tissue and also coagulates small blood vessels.<sup>11</sup> Nd:YAG laser is hypothesized to primarily treat keloids by damaging deep dermal blood vessels.<sup>12</sup> Also, it may directly suppress fibroblast collagen expression.<sup>12</sup> Due to its wavelength (1,064 nm), however, the depth of penetration of the Nd:YAG laser is much greater, a property shown to be useful in the treatment of Keloid scars. PDL is hypothesized to treat keloids by selective damage of blood vessels that supply the scar.<sup>13</sup> With a wavelength of 595nm or 585nm, oxyhemoglobin is the target chromophore of pulse dye laser (PDL). The near infrared diode laser has energy and wave length characteristics that specifically target the soft tissues.<sup>14</sup> The 980 nm diode laser is selectively absorbed by haemoglobin and selectively destroys blood vessels, minimising injury to the surrounding healthy skin. The light energy released by the diode laser transforms into heat, resulting in the vaporization of cells, a

process referred to as the photothermal effect.<sup>14</sup>

Radiofrequency tissue volume reduction (RFTVR) uses very low levels of radiofrequency energy to create controlled protein denaturation or necrosis in soft-tissue structures.<sup>15</sup> Radiofrequency ablation can be considered as minimally invasive treatment modality with no major disadvantages.<sup>16</sup> Because of its mechanism of action, RFTVR appeared suitable for treatment of keloids.

Photodynamic therapy (PDT) is an established mode of treatment for skin conditions such as Basal Cell Carcinoma, Actinic Keratosis and Bowens Disease.

This therapy is a non-invasive therapy that utilizes light treatments along with an application of a photosensitizing agent (PA). The PA is applied to the skin, causing the skin to become more susceptible, or receptive, to light.<sup>17</sup> Once the incubation period of PA is complete, light of a specific wave length is directed onto the area to be treated, activating the protoporphyrin 9 (PpIX) and resulting in the formation of cytotoxic reactive oxygen species. This causes cell apoptosis or necrosis, membrane and mitochondrial damage and activates many signalling molecules, e.g. TNF- $\alpha$ , interleukins 1 and 6.<sup>18</sup> The potential mechanism of PDT in keloid may involve modulation of the growth factor and cytokine expression.<sup>18</sup>

Long-wave length UVA1 is different from other UV phototherapies because it offers deeper penetration as well as targeting fibrosis and other structures, i.e. fibroblasts, T-lymphocytes, Langerhans cells, mast cells, endothelial cells.<sup>19</sup> UVA1 (340-400nm) acts deeper in the dermis and even in the subcutaneous tissue. Moreover, around 20% of the radiation reaches vascular system, which, according to some authors, provides grounds for a potential systemic action of this radiation range.<sup>19</sup> UVA1 irradiation has been reported to be effective for the treatment of morphea and systemic sclerosis through the induction of collagenase I [matrix metallo proteinase I (MMP-1)] production by fibroblasts and decreased synthesis of procollagen. The efficacy of UVA1 for the treatment of keloid scarring may be partly the result of this action.<sup>20</sup>

## Method


A systematic review of the literature was performed for the original articles related to the treatment of keloids. The search terms ‘keloids’ and ‘lasers’ or ‘radiofrequency’ or ‘PDT’ or ‘UVA1’ was entered into a search of the National Library of Medicine’s PubMed

Database. The search returned a total of 188 sources, of which, 26 articles met our inclusion criteria. Published clinical trials, case series, case reports, retrospective studies and letters reporting on keloid treatment using ablative lasers, non-ablative lasers, radiofrequency, PDT or UVA1 were included in this review. Unfortunately, randomized clinical trials on the relevant topic were not found. Only human studies and English language articles were selected. Articles about other skin conditions or scar types other than keloids, including those that collectively mentioned hypertrophic scars and keloids, were excluded. In vitro studies were excluded. Figure 1 shows schematic diagram of search strategy listing the articles that met inclusion or exclusion criteria and Table 1 summarizes the characteristics of the 26 studies included in this review.

### Laser therapy

Apfelberg DB et al reported the earliest study on laser treatment for keloids in 1984.<sup>21</sup> Thirteen patients with well-established keloid scars of the trunk or earlobe were treated with either multiple-bore-hole argon technique alone or in combination with total excision with the CO<sub>2</sub> laser. Only one patient with an earlobe keloid treated with argon laser alone showed total disappearance of keloid, all other patients had no improvement. In 1989, Apfelberg DB et al again treated seven patients with keloid on the trunk, nuchal region, back, and earlobe.<sup>22</sup> Under local anesthesia, the keloids were excised sharply down to the base by CO<sub>2</sub> laser. Only one patient with earlobe keloid showed great improvement after only nine months' follow-up, all other patients had recurrence.

Ang CC et al reported case records of 16 patients with earlobe keloids.<sup>23</sup> The patients received different treatment modalities including CO<sub>2</sub> laser ablation, or cold steel surgery, or combined surgery and CO<sub>2</sub> laser ablation, or 40 mg/ml of intralesional triamcinolone acetonide. Both the CO<sub>2</sub> laser ablation and cold steel surgery were equally useful in reducing the size of the earlobe keloids, but were not effective in preventing regrowth of the keloids, even with adjunctive intralesional steroids. In contrast to the above studies, Morosolli AR et al observed a very good esthetic and functional result in a patient with an earlobe keloid treated with CO<sub>2</sub> laser with a 0.8-mm focus, 7 W, a power density of 2.5 W/cm<sup>2</sup>, in a continuous mode.<sup>24</sup> Similarly, Nicoletti G et al reported effective and well-tolerated treatment of keloids by CO<sub>2</sub> laser.<sup>25</sup> Fifty patients with moderate to severe keloids received regional treatments (deltoid, elbow, chin, and ear) with a high-energy pulsed CO<sub>2</sub> laser. Diminished scar bulk with a reduction in scar height and textural improvement was noted in all the patients. Scrimali L et al compared the effect of laser CO<sub>2</sub> versus radiotherapy following surgical excision in the treatment of keloid and found that CO<sub>2</sub> laser after surgical excision of keloids has great results with no recurrence and without the risk of carcinogenesis.<sup>26</sup> Yang Q et al reported a study with successful use of combination approach.<sup>27</sup> One hundred and fifty one sites of keloids in 122 patients were treated with combination methods of continuous-wave CO<sub>2</sub> laser, ultra-pulse CO<sub>2</sub> laser and 32P radiation. One hundred eleven of 151 evaluated sites scored "excellence" and 40 belonged to "effectiveness". These patients demonstrated local control and have remained free of local recurrence for more than two years.



**Figure 1:** Schematic diagram of search strategy listing the articles that met inclusion or exclusion criteria.

Studies on laser therapy for keloids have shown more exciting results with PDL comparing to CO2 lasers. However, multiple treatments (>six) were required to yield better results than fewer treatments: 79% versus 50%, respectively. Twelve months after final PDL treatments, keloid regression ( $\geq 50\%$ ) had occurred in 26 out of 30 patients.<sup>28</sup> Another study showed better result with PDL only after three sessions of treatment.<sup>29</sup> Using the Vancouver scar scale (VSS), there was an average decrease of  $20.85 \pm 12.33\%$  after PDL treatment. Eke U et al reported on the successful use of surgical shave-excision followed by single-pass PDL therapy for the treatment of keloid.<sup>30</sup> Similarly, Cannarozzo G et al also reported a successful use of flash lamp pumped PDL.<sup>31</sup> This study recruited 59 patients who received four to six treatment sessions with a flash lamp pumped PDL. A total of 29 patients out of 59 achieved excellent clearance, 15 patients achieved good to moderate clearance, and 12 patients obtained slight improvement. Only three subjects had little or no removal of their lesion. Martin MS et al combined fractional CO2 laser with PDL as well as the injection of triamcinolone acetonide into the keloids refractory to solitary treatments of triamcinolone acetonide injection and other laser modalities.<sup>32</sup> Treatments were carried out once per month for seven sessions. After five sessions, dramatic improvement in the lesions was seen.

Recently, studies on other types of lasers including Nd:YAG lasers, Er:YAG lasers, and 980nm diode laser with adjunctive intralesional or topical corticosteroids have shown good results in treating keloids.<sup>14,33,34</sup> The success rate in these studies varied from 50% to 75%.<sup>14,34</sup> More recently, Chen XE et al reported a successful use of long-pulsed Nd:YAG laser in combination with intralesional injection of diprospan and 0.5 ml 5-fluorouracil.<sup>35</sup> In terms of invasiveness, two studies provided least invasive therapy.<sup>34-36</sup> Cavalie M et al treated 23 patients with 70 keloids with a 2940-nm ablative fractional erbium laser and topical betamethasone cream.<sup>34</sup> The median percentage of improvement was 50% and a recurrence was observed for eight lesions at 18 months follow up. Similarly, Park JH et al treated keloids with an ablative fractional erbium-YAG laser and an intralesional injection or topical application of corticosteroid and concluded this treatment a promising modality for the treatment of keloids.<sup>36</sup>

## Radiofrequency

Some small studies have proven the clinical safety and efficacy of RF in the treatment of keloids, especially in

combination with adjuvant ILCS. It was in 2011, when Kai Fruth et al for the first time applied RFTVR in 14 patients with keloids of the auricle.<sup>15</sup> In six patients, RFTVR was the sole treatment modality applied, and in seven patients IL steroid injection was also performed. Good cosmetic results were achieved in 10 of 14 patients. In 2013, Klockars T et al presented the second paper on this promising novel treatment option.<sup>37</sup> They applied RF ablation in 11 patients (13 auricles) with single treatment session for all except one patient who was treated three times with three and 13 months interval. The effect of RF ablation was excellent in six auricles, good in five auricles and moderate in one auricle. In 2015, Weshay AH et al presented the study on the combined effect of RF and IL steroids in the treatment of keloids.<sup>38</sup> It was a pilot study on 18 patients who were subjected to three to four sessions of RF followed by IL steroid injection. A significant reduction of volume of all lesions in all patients was noted, with a mean volume reduction of 95.4%.

## Photodynamic therapy

In 2010, Nie Z et al reported the first study on PDT of keloids.<sup>18</sup> It was a case report of the patient who had keloid under her chin for four years that had failed to respond to several other treatments, including surgical resection, but showed substantial improvement with PDT. After five sessions of MAL-PDT over a period of 5 months, the patient's lesion had considerably reduced in size and become flattened and there was no recurrence at 1-year follow-up. Ud-Din S et al also, in their clinical trial of 20 patients, proved the efficacy of PDT for keloids.<sup>39</sup> The patients underwent three treatments of MAL-PDT at weekly intervals. All patients showed marked improvement except one patient who experienced recurrence of KD. All other patients had no recurrence at nine-month follow-up.

## UVA1 irradiation

Asawanonda P et al reported the first study on the successful use of UVA1 irradiation for the treatment of keloids in 1999.<sup>40</sup> It was a case report where patient received 2860 J/cm<sup>2</sup> of UVA1 irradiation and responded well to the treatment. In contrary to this article reporting a successful treatment, Hannuksela-Svahn A et al found no effect of UVA1 irradiation on stable keloids.<sup>41</sup> This was a study performed on three patients with a several years history of a stable keloid secondary to tuberculin vaccine in the one patient and to acne in the other 2 patients. The patients received 1700, 1800 and 1500 J/cm<sup>2</sup> of UVA1 irradiation given strictly to the lesion alone.

**Table 1: characteristics of the studies demonstrating the efficacy of various treatment modalities for keloids.**

Authors/reference	Study type	No. of patients/ FSP	No. & Site of keloid	Intervention method	Treatment regimen	Outcome	Follow up/Recurrence
Kassab AN et al <sup>14</sup>	Clinical trial, non-blinded, no control	12/ type 3 to type 5	16 ear lobe keloids	Single repeated mode of 4 s duration, at power 5 W with an energy fluence 20 J/cm <sup>2</sup> was applied via 980-nm diode laser plus IL CS	2-5 sessions at 3w interval	Total success rate of 75% was seen	12m/none
Apfelberg DB et al <sup>21</sup>	Clinical trial, control	13/-	Trunk & earlobe	Multiple-bore-hole argon technique & total excision with CO2 laser	3 sessin at 6w interval	One patient with an earlobe keloid responded to treatment, all other patients had no improvement.	6m or more/2 patients showed recurrence
Apfelberg DB et al <sup>22</sup>	Case series	7/-	9 keloids at back, trunk,ear lobe, & nuchae	Excision with co2 laser	-	The long-term benefits of keloid excision with co2 laser is not demonstrated in this case series.	10-22m/8 of 9 keloids recurred
Ang CC et al <sup>23</sup>	Retrospective	16/-	Earlobe keloids	8 patients CO2 laser ablation, 6 patients cold steel surgery, 1 patient both surgery & CO2 laser ablation, & 1 patient received only IL CS	-	Both CO2 laser ablation & cold steel surgery were equally useful in reducing size of earlobe keloids, but were not effective in preventing regrowth of keloids, even with adjunctive IL CS	1-24m/ recurrence of keloid growth at 2-18 weeks post procedure
Morosoli AR et al <sup>24</sup>	Case report	1/-	Earlobe keloid	CO2 with an 0.8-mm focus, 7 W, a power density of 2.5 W/cm <sup>2</sup> , in a continuous mode	-	Very good esthetic and functional result was seen	6m/ none
Nicoletti G et al et al <sup>25</sup>	Clinical trial, non-blinded, no control	50/ type I-IV	Deltoid, elbow, chin, & ear	High-energy pulsed CO2 laser therapy followed by LA of HA ointment to the irradiated skin. At the end of treatment cycles, a combined treatment with adjuvant silicone gel sheeting & pressure massage therapy was prescribed	4 sessions of laser therapy	CO2 laser appeared effective & well tolerated for treatment of keloids, avoiding adverse effects & lengthy recovery time.	12m/-
Scrimali L et al <sup>26</sup>	Clinical trial, non-blinded, no control	4/-	Earlobe and retroauricular region	Surgical excision of scar, after 10-12 days, when the suture was removed, they were treated monthly with a CO2 laser	Every month for 6 months plus same plast gel twice a day	Compared to RT, CO2 laser after surgical excision of keloids has shown great results with no recurrence	1 year/None
Yan D et al <sup>27</sup>	Clinical trial, non-blinded, no control	122/-	151 keloids at multiple sites	Combination methods of lasers & 32P radiation	-	Based on therapeutic effective criteria, 111 of 151 evaluated sites scored "excellence," and 40 scored "effectiveness."	2y/none
Kuo YR et al <sup>28</sup>	Clinical trial, non-blinded, no control	30/	Keloids at multiple sites	flashlamp pumped PDL with Wavelength of 585 nm, PD 450 ms & spot size 5 mm.	1-11 sessions at 2m interval	More than six PDL treatments at 2-month intervals provided the best results.	12m/none
Yang Q et al <sup>29</sup>	Controlled clinical trial	26/ type III & IV	Chest or scapular areas keloid	PDL with PD of 1.5ms, spot size 7mm, DCD duration 20 ms/delay 10 ms & fluence of 10 J/cm <sup>2</sup>	3 sessions at 3-4w interval	According to realtime PCR, the CTGF mRNA was significantly down-regulated after PDL treatment in 80.77% of patients as compared to the control group	-
Eke U et al <sup>30</sup>	Case series	3/ type VI	Facial and posterior chest wall keloid	Surgical shave-excision followed by 4 sessions single-pass PDL therapy	-	Some hypopigmentation was noted at treated sites but this gradually improved and patient was satisfied with treatment	18m/none
Cannarozzo G et al <sup>31</sup>	Clinical trial, non-blinded, no control	59/ type I-IV	Abdomen, chest, earlobe	Vaporized with a CO2 ultrapulsed laser before the first FPDL or FPDL alone.	4-6 sessions at 1m interval	Of 59 patients, 29 achieved excellent clearance, 15 achieved good-moderate clearance, 12 obtained slight clearance, & 3 patients had little or no improvement	6m/-
Martin MS et al <sup>32</sup>	Case report	1/-	Upper back	Combination of the Affirm CO2 fractional laser Cynergy PDL & triamcinolone acetonide injection	7 sessions at 1 month interval	Dramatic improvement after 5 sessions	-
Rossi A et al <sup>33</sup>	Retrospective	44/ type I through type VI	-	Nd:YAG plus IL CS or Nd:YAG only or IL CS only	6 sessions at 3w interval for Nd:YAG plus IL CS group	Nd:YAG plus IL CS group showed best result with 100% patients showing 75% reduction in thickness & erythema of keloids.	-
Cavalié M et al <sup>34</sup>	Retrospective	23/-	70 keloids at chest, shoulder, arm, face, ear, & neck	2940-nm ablative fractional erbium laser combined with topical high potent CS cream	Patients had 1 laser session every other week with 4 crossed passes for a total of 20% coverage.	The median percentage of improvement was 50%	8 months/ recurrence in 8 lesions

Table 1 contd.

Authors/reference	Study type	No. of patients/ FSP	No. & Site of keloid	Intervention method	Treatment regimen	Outcome	Follow up/Recurrence
Chen XE et al <sup>85</sup>	Randomized blinded clinical trial	69/-	One lesion (preferably on the trunk or proximal extremities) per patient	ILCS or ILCS+ 5FU or ILCS+ 5FU+1,064nm Nd:YAG laser with single pulse at energy density of 90.100 J/cm <sup>2</sup> , pulse width of 12 msec	3 sessions at 1m interval	Combination of ILCS+ 5FU + Nd:YAG was the most efficacious therapy	3m/none
Park JH et al <sup>86</sup>	Clinical trial, non-blinded, no control	10/-	10 keloids on the left shoulder after BCG vaccination	Ablative fractional erbium-YAG laser+ILCS or topical CS	4 sessions at 6w interval	Both treatments showed promising result	12w/all keloids appeared to be recurring
Shih PY et al <sup>85</sup>	Case report	1/ type IV	Large keloids over V-region of chest	Single course of PDL was used 1w after last IL steroid injection	IL CS weekly for 6visits, biweekly for 8visits, biweekly for 5visits, & monthly for 5visits followed by 1 session of PDL	Rapid recurrence of keloid (previously flattened with IL CS) within 1 week of PDL treatment for telangiectasia.	At 1w follow up previously flattened keloid enlarged substantially
Fruth K et al <sup>15</sup>	Clinical trial, non-blinded, no control	14/-	keloids of auricle	6 patients received only RFTVR, 7 patients received RFTVR plus ILCS	1-7 sessions	Of 14 patients, 10 achieved Good cosmetic results, 3 were refractive to treatment, & 1 showed progressive disease despite treatment.	2.92m/none
Klockers T et al <sup>87</sup>	Retrospective	11/-	Keloidsof auricle	RF ablation. electrode tip was inserted into keloid, & preset energy of 10W was applied into keloid tissue until automatic cut-off.	1-3 session at 3-13 m interval	Effect was excellent in 6 auricles, good in 5 auricles and moderate in 1 auricle	-
Weshay AH et al <sup>88</sup>	Pilot study	18/ type II to IV	19 keloids on head and neck	RF followed by IL steroid injection	3 to 5 sessions of RF followed by IL steroid injection.	Significant reduction of volume of all lesions in all patients with a mean volume reduction of 95.4%	5 years/ small scar recurred in 10% cases
Nie Z et al <sup>18</sup>	Case report	1/-	Keloid under the chin	3 hours after MAL application, the area was irradiated with red light from an LED source at wavelength 633 nm, at a dose of 37 J/cm <sup>2</sup> .	5 sessions of MAL-PDT were given over a 5-month period.	Keloid had considerably reduced in size and become flattened	1y/no recurrence
Ud-Din S et al <sup>89</sup>	Clinical trial, non-blinded, no control	20/-	multiple site keloids	MAL applied 3 h prior to PDT. Irradiation was conducted using a red light with a wavelength of 630 nm & light dosage was administered at 37 J/cm <sup>2</sup> .	3 sessions at 1w interval	PDT reduces scar formation in Keloid evidenced by decreased blood flow, increased pliability, decreased collagen & haemoglobin levels.	9m/ Only 1 patient with a keloid in a stressprone anatomical location had recurrence
Asawanonda P et al <sup>90</sup>	Case report	1/ type IV	Single keloid on chest	UV-A1, generated by a light box fitted with a UV-A1 filter allowing only wavelengths between 340 and 450 nm	4 times weekly for 6 weeks	Improvement as early as 3 <sup>rd</sup> week of treatment, and after 6 weeks, marked softening and flattening were noted	-
Hannuksela-Svahn A et al <sup>91</sup>	Case series	3/-	Shoulder & chest keloid	100 J/cm <sup>2</sup> of UVA1 irradiation with a final CD of 1700, 1800 & 1500 J/cm <sup>2</sup>	3 times a week for 5-6w	Treatment was tolerated well, & 2 of the patients experienced subjectively softening of keloid but none had any macroscopic reduction of the scar.	-
Polat M/42	Case series	2/type II & type III	Keloid on chest and heel	High-dose UVA1 355 nm laser. 160 J/cm <sup>2</sup> 3 times a week for the first 2 weeks & then 180 J/cm <sup>2</sup> for 2 weeks, 230 J/cm <sup>2</sup> for 3 weeks, & 250 J/cm <sup>2</sup> for 6 weeks	3 sessions a week for up to 12 weeks	An improved VSS score was observed. However, applying UVA1 therapy is time consuming.	-

Note- m: months, y: year, w: week, PD: pulse duration, ms: microsecond, IL: intralesional, FSP: Fitzpatrick's Skin Phototypes, RT: radiotherapy, PDL: pulsed dye laser, FPD: Flash lamp pulsed dye laser, CS: corticosteroid, LA: local application, HA: hyaluronic acid, RF: radiofrequency, CD: cumulative dose, RFTVR: Radiofrequency tissue volume reduction, MAL: Methyl aminolevulinate, PDT: photodynamic therapy, VSS: Vancouver Scar Scale, 5FU: 5fluorouracil

The treatment was tolerated well, and two of the patients experienced subjectively softening of the keloid but none had any macroscopic reduction of the scar. The lack of response in the second experiment might be due to low dose of UVA1 comparing to the first study where high dose of UVA1 (2860 J/cm<sup>2</sup>) was used. Recently in 2016, Polat M et al presented the results from two patients who underwent high dose UVA1 laser therapy.<sup>42</sup> The treatment protocol applied in this study was: 160 J/cm<sup>2</sup> three times a week for the first two weeks then 180 J/cm<sup>2</sup> for two weeks, 230 J/cm<sup>2</sup> for three weeks, and 250 J/cm<sup>2</sup> for six weeks for one patient. 140 J/cm<sup>2</sup> three times a week for the first three weeks, and then at 160 J/cm<sup>2</sup> for three weeks, 180 J/cm<sup>2</sup> for two weeks, 230 J/cm<sup>2</sup> for two weeks, and 250 J/cm<sup>2</sup> for two weeks for another patient. An improved VSS score was observed following treatment and complaint of itching and tenderness decreased significantly.

## Discussion

In the past, the most recommended treatment strategy for keloid has been prophylaxis using silicone gel sheeting or paper tape starting on the second week after wounding, combined with other treatments, including massage, pressure therapy and intralesional corticotherapy, depending on each patient and scar's origin and type.<sup>43</sup> None of these therapeutic options has been found completely effective and satisfactory. Moreover, patients with keloid scars suffer a severe impairment of quality of life, by causing physical, psychological and social sequelae.<sup>44</sup> Recently, the promising results of some big and small studies has drawn attention to the possible beneficial effects of upcoming therapeutic modalities like lasers, radiofrequency, photodynamic therapy, and UVA1 irradiation. Among lasers, CO<sub>2</sub> laser was seen to be effective for keloids as a solo therapy.<sup>24,25</sup> It was also effective as an adjuvant therapy following surgical excision<sup>26</sup>. Results with other lasers like PDL, 980nm diode laser, Nd:YAG lasers, and Er:YAG lasers were also good in terms of patient satisfaction and recurrence.<sup>27-30,33,34</sup> In these studies, combination approach showed better result than solo therapy. Laser treatments were mainly combined with surgical excision or ILCS.<sup>26,27,30,33</sup> However, not all studies with laser showed exciting results. 2 studies with CO<sub>2</sub> laser and 1 study with PDL showed complete recurrence of

keloids.<sup>22,23,45</sup> These different outcome conclusions are likely due to variations in keloid size, location and duration and also variations in treatment dosimetry and protocols.

Similarly, studies with RF showed better result when adjunctive ILCS was used.<sup>38</sup> Three studies on RF reviewed here, all of which showed good result with no recurrence except one study where a small scar recurred in 10% of cases at five year follow up.<sup>15,37,38</sup> However, none of the other studies did this long duration follow up of five years. Both the studies on PDT reviewed here used MAL as a photosensitizing agent and irradiated the lesions using a red light with a wave length of 630 nm and light dosage at 37 J/cm<sup>2</sup>.<sup>18,39</sup> All the patients showed marked improvement and no recurrence except one patient with a keloid in a stress prone anatomical location that recurred.<sup>39</sup> Unfortunately, studies on UVA1 failed to give exciting results. Three studies on UVA1 reviewed here reported the improvement in symptoms like itching and tenderness, but none reported the reduction of scar volume.<sup>40-42</sup>

Unfortunately, most of the studies on keloids are non-controlled arm, non-blinded, and non-randomized. The challenge of conducting double-blind RCTs for keloid treatment is the inherent difficulty in blinding patients and treatment operators. This may be the reason why cutaneous scar management has relied mainly on the experience of practitioners rather than on the results of large-scale randomized, controlled trials and evidence-based studies.<sup>43</sup>

## Conclusion

In the case of keloids, combination approach is the best treatment modality. Successful therapeutic management need to address the conditions that initiate keloid formation, if not, keloid recurrence is likely and optimal management may not be achieved. In addition, it is highly desirable that many standard practices and new emerging therapies undergo large-scale studies with long-term follow-up before being recommended conclusively as alternative therapies for the treatment of keloid. Moreover, RCTs are urgently needed.

**Financial disclosure:** None

**Conflict of interest to disclosure:** None declared.

## References

1. Louw L. The keloid phenomenon: progress toward a solution. *Clin Anat.* 2007; 20(1): 3-14. <https://doi.org/10.1002/ca.20374>
2. Shaffer JJ, Taylor SC, Cook-Bolden F. Keloidal scars: A review with a critical look at therapeutic options. *J Am Acad Dermatol.* 2002; 46:S63–97. <https://doi.org/10.1067/mjd.2002.120788>
3. Mrowietz U, Seifert O. Keloid scarring: new treatments ahead. *Actas Dermosifiliogr.* 2009; 100: 75–83. [https://doi.org/10.1016/S0001-7310\(09\)73382-4](https://doi.org/10.1016/S0001-7310(09)73382-4).
4. Rawlings AV. Ethnic skin types: are there differences in skin structure and function? *Int J Cosmet Sci.* 2006; 28(2): 79-93. <https://doi.org/10.1111/j.1467-2494.2006.00302.x>
5. Kelly AP. Keloids. *Dermatol Clin.* 1988 Jul;6(3):413-24. [https://doi.org/10.1016/S0733-8635\(18\)30653-3](https://doi.org/10.1016/S0733-8635(18)30653-3)
6. Chiu LL, Sun CH, Yeh AT, Torkian B, Karamzadeh A, Tromberg B et al. Photodynamic Therapy on Keloid Fibroblasts in Tissue-Engineered Keratinocyte-Fibroblast Co-Culture. *Lasers Surg Med.* 2005; 37:231–44. <https://doi.org/10.1002/lsm.20213>
7. Gauglitz GG, Korting HC, Pavicic T, Ruzicka T, Jeschke MG. Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. *Mol Med* 2011; 17:113-25. <https://doi.org/10.2119/molmed.2009.00153>
8. Barolet D, Boucher A. Prophylactic low-level light therapy for the treatment of hypertrophic scars and keloids: a case series. *Lasers Surg Med.* 2010; 42(6): 597-601. <https://doi.org/10.1002/lsm.20952>
9. Alster TS. Cutaneous resurfacing with CO2 and erbium: YAG lasers: preoperative, intraoperative, and postoperative considerations. *Plast Reconstr Surg* 1999; 103: 619–32. <https://doi.org/10.1097/00006534-199902000-00040>.
10. Wagner JA, Paasch U, Bodendorf MO, Simon JC, Grunewald S. Treatment of keloids and hypertrophic scars with the triple-mode Er:YAG laser: A pilot study. *Med Laser Appl* 2011; 26: 10–5. <https://doi.org/10.1016/j.mla.2010.10.001>.
11. Poetschke J, Gauglitz GG. Current options for the treatment of pathological scarring. *J Dtsch Dermatol Ges.* 2016; 14(5): 467-77. [https://doi.org/10.1111/ddg.13027\\_g](https://doi.org/10.1111/ddg.13027_g)
12. Philipp CM, Scharschmidt D, Berlien HP. Laser treatment of scars and keloids – How we do it. *Med Laser Appl* 2008; 23: 79–86. <https://doi.org/10.1016/j.mla.2008.01.005>
13. Garden JM, Tan OT, Kerschmann R, Boll J, Furumoto H, Anderson RR. Effect of dye laser pulse duration on selective cutaneous vascular injury. *J Invest Dermatol* 1986; 87:653–657. <https://doi.org/10.1111/1523-1747.ep12456368>.
14. Kassab AN, El Kharbotly A. Management of ear lobule keloids using 980-nm diode laser. *Eur Arch Otorhinolaryngol.* 2012; 269(2): 419-23. <https://doi.org/10.1007/s00405-011-1632-9>
15. Fruth K, Gouveris H, Kuelkens C, Mann WJ. Radiofrequency tissue volume reduction for treatment of auricle keloids. *Laryngoscope.* 2011; 121(6): 1233-6. <https://doi.org/10.1002/lary.21782>
16. Bäck LJ, Liukko T, Sinkkonen ST, Ylikoski J, Mäkitie AA. Complication rates of radiofrequency surgery in the upper airways: a single institution experience. *Acta Otolaryngol.* 2009; 129, 1469–73. <https://doi.org/10.3109/00016480802706719>.
17. Keyal U, Bhatta AK, Wang XL. Photodynamic therapy for the treatment of different severity of acne: A systematic review. *Photodiagnosis Photodyn Ther.* 2016; 14:191-9. <https://doi.org/10.1016/j.pdpdt.2016.04.005>.
18. Nie Z, Bayat A, Behzad F, Rhodes LE. Positive response of a recurrent keloid scar to topical methyl aminolevulinate-photodynamic therapy. *Photodermatol Photoimmunol Photomed.* 2010; 26(6): 330-2. <https://doi.org/10.1111/j.1600-0781.2010.00539.x>
19. Osmola-Mańkowska A, Dańczak-Pazdrowska A, Olek-Hrab K, Silny W. Role of UVA1 phototherapy in treatment of scleroderma and scleroderma-like disorders. *Centr Eur J Immunol* 2012; 37 (4): 391-8 <https://doi.org/10.5114/ceji.2012.32731>.
20. Petersen MJ, Hansen C, Craig S. Ultraviolet A irradiation stimulates collagenase production in cultured human fibroblasts. *J Invest Dermatol* 1992; 99:440–4. <https://doi.org/10.1111/1523-1747.ep12616142>
21. Apfelberg DB, Maser MR, Lash H, White D, Weston J. Preliminary results of argon and carbon dioxide laser treatment of keloid scars. *Lasers Surg Med.* 1984; 4(3):283-90. <https://doi.org/10.1002/lsm.1900040309>
22. Apfelberg DB, Maser MR, White DN, Lash H. Failure of carbon dioxide laser excision of

- keloids. *Lasers Surg Med.* 1989; 9(4): 382-8. <https://doi.org/10.1002/lsm.1900090411>
23. Ang CC, Tay YK, Kwok C. Retrospective analysis of earlobe keloids treated with the carbon dioxide laser ablation or cold steel debulking surgery. *J Cosmet Laser Ther.* 2013; 15(5): 271-3. <https://doi.org/10.3109/14764172.2013.769275>
  24. Morosolli AR, De Oliveira Moura Cardoso G, Murilo-Santos L, Niccoli-Filho W. Surgical treatment of earlobe keloid with CO2 laser radiation: Casereport and clinical standpoints. *J Cosmet Laser Ther.* 2008; 10: 226-30. <https://doi.org/10.1080/14764170802307957>
  25. Nicoletti G, De Francesco F, Mele CM, Cataldo C, Grella R, Brongo S et al. Clinical and histologic effects from CO2 laser treatment of keloids. *Lasers Med Sci.* 2013; 28(3): 957-64. <https://doi.org/10.1007/s10103-012-1178-0>
  26. Scrimali L, Lomeo G, Tamburino S, Catalani A, Perrotta R. Laser CO2 versus radiotherapy in treatment of keloid scars. *J Cosmet Laser Ther.* 2012; 14(2): 94-7. <https://doi.org/10.3109/14764172.2012.671524>
  27. Yan D, Zhao B, Yang H, Zhu B, Wang J. A combination of nonoperative treatment modalities used for treatment of keloids. *Dermatol Ther.* 2014 ;27(1):48-51. <https://doi.org/10.1111/dth.12044>
  28. Kuo YR, Jeng SF, Wang FS, Chen TH, Huang HC, Chang PR et al. Flashlamp pulsed dye laser (PDL) suppression of keloid proliferation through down-regulation of TGF-beta1 expression and extracellular matrix expression. *Lasers Surg Med.* 2004; 34(2): 104-8. <https://doi.org/10.1002/lsm.10206>
  29. Yang Q, Ma Y, Zhu R, Huang G, Guan M, Avram MM et al. The effect of flashlamp pulsed dye laser on the expression of connective tissue growth factor in keloids. *Lasers Surg Med.* 2012; 44(5): 377-83. <https://doi.org/10.1002/lsm.22031>
  30. Eke U, Diaz C, Abdullah A. Keloid scars in type VI skin successfully treated with combined surgery and pulsed dye laser therapy. *Br J Dermatol.* 2013; 168(6): 1360-2. <https://doi.org/10.1111/bjd.12159>
  31. Cannarozzo G, Sannino M, Tamburi F, Morini C, Nisticò SP. Flash-lamp pulsed-dye laser treatment of keloids: results of an observational study. *Photomed Laser Surg.* 2015; 33(5): 274-7. <https://doi.org/10.1089/pho.2015.3895>
  32. Martin MS, Collawn SS. Combination treatment of CO2 fractional laser, pulsed dye laser, and triamcinolone acetonide injection for refractory keloid scars on the upper back. *J Cosmet Laser Ther.* 2013;15(3):166-70. <https://doi.org/10.3109/14764172.2013.780448>
  33. Rossi A, Lu R, Frey MK, Kubota T, Smith LA, Perez M. The use of the 300 microsecond 1064 nm Nd:YAG laser in the treatment of keloids. *J Drugs Dermatol.* 2013; 12(11): 1256-62.
  34. Cavalié M, Sillard L, Montaudié H, Bahadoran P, Lacour JP, Passeron T. Treatment of keloids with laser-assisted topical steroid delivery: a retrospective study of 23 cases. *Dermatol Ther.* 2015; 28(2): 74-8. <https://doi.org/10.1111/dth.12187>
  35. Chen XE, Liu J, Bin Jameel AA, Valeska M, Zhang JA, Xu Y et al. Combined effects of long-pulsed neodymium-yttrium-aluminum-garnet laser, diprosan and 5-fluorouracil in the treatment of keloid scars. *Exp Ther Med.* 2017;13(6):3607-12. <https://doi.org/10.3892/etm.2017.4438>
  36. Park JH, Chun JY, Lee JH. Laser-assisted topical corticosteroid delivery for the treatment of keloids. *Lasers Med Sci.* 2017;32(3):601-8. <https://doi.org/10.1007/s10103-017-2154-5>
  37. Klockars T, Bäck LJ, Sinkkonen ST. Radiofrequency ablation for treatment of auricular keloids: our experience in eleven patients. *Clin Otolaryngol.* 2013; 38(5): 381-5. <https://doi.org/10.1111/coa.12169>
  38. Weshay AH, Abdel Hay RM, Sayed K, El Hawary MS, Nour-Edin F. Combination of radiofrequency and intralesional steroids in the treatment of keloids: a pilot study. *Dermatol Surg.* 2015; 41(6): 731-5. <https://doi.org/10.1097/DSS.0000000000000360>
  39. Ud-Din S, Thomas G, Morris J, Bayat A. Photodynamic therapy: an innovative approach to the treatment of keloid disease evaluated using subjective and objective non-invasive tools. *Arch Dermatol Res.* 2013; 305(3): 205-14. <https://doi.org/10.1007/s00403-012-1295-4>
  40. Asawanonda P, Khoo LSW, Fitzpatrick TB, Taylor CR. UV-A1 for keloid. *Arch Dermatol* 1999; 135: 348 - 9. <https://doi.org/10.1001/archderm.135.3.348>
  41. Hannuksela-Svahn A, Grandal OJ, Thorstensen T, Christensen OB. UVA1 for treatment of keloids. *Acta Derm Venereol.* 1999; 79(6): 490. <https://doi.org/10.1080/000155599750010076>
  42. Polat M, Kaya H, Şahin A. A New Approach in the Treatment of Keloids: UVA-1 Laser. *Photomed Laser Surg.* 2016; 34(3): 130-3. <https://doi.org/10.1089/pho.2015.4046>

43. Mustoe TA, Cooter RD, Gold MH, Hobbs FD, Ramelet AA, Shakespeare PG et al. International Advisory Panel on Scar Management. International clinical recommendations on scar management. *Plast Reconstr Surg* 2002; 110(2): 560–71. <https://doi.org/10.1097/00006534-200208000-00031>
44. Leventhal D, Furr m, Reiter D. Treatment of keloids and hypertrophic scars. *Arch Facial Plast Surg* 2006; 8:362–8. <https://doi.org/10.1001/archfaci.8.6.362>
45. Shih PY, Chen HH, Chen CH, Hong HS, Yang CH. Rapid recurrence of keloid after pulse dye laser treatment. *Dermatol Surg*. 2008;34(8):1124-7. <https://doi.org/10.1111/j.1524-4725.2008.34225.x>